Буфексамак

Key facts

Drug.H

17

Drug.N

1

Drug.O

3

Drug.IUPAC_name

2-(4-butoxyphenyl)-N-hydroxyacetamide

Drug.image

Bufexamac Structural Formula V2.svg

Drug.image_class

skin-invert-image

Drug.legal_status

OTC

Drug.routes_of_administration

Topical, rectal

Drug.excretion

Renal

Drug.IUPHAR_ligand

7498

Drug.CAS_number

2438-72-4

Drug.ATC_prefix

M01

Drug.ATC_suffix

AB17

Drug.PubChem

2466

Drug.ChEMBL

94394

Drug.ChemSpiderID

2372

Drug.UNII

4T3C38J78L

Drug.KEGG

D01271

via Wikipedia infobox

Chemical data

Formula

C12H17NO3

Molecular weight

223.27 g/mol

IUPAC name

2-(4-butoxyphenyl)-N-hydroxyacetamide

via PubChem

Drug data · ChEMBL

Max clinical phase

Approved

Molecule type

Small molecule

Indications

rheumatic disease, Myalgia, Arthralgia

via ChEMBL · EBI

• Bufexamac ameliorates LPS-induced acute lung injury in mice by targeting LTA4H.Scientific reports · 2016
• Effects of Bufexamac, a class IIb HDAC inhibitor, on behavior and neuropathological features in an Aβ-induced rat model of Alzheimer's disease.Experimental gerontology · 2025
• [Bufexamac-induced pigmented purpuric eruption].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2009
• In vitro photobiochemical characterization of sulfobutylether-β-cyclodextrin formulation of bufexamac.Journal of pharmaceutical and biomedical analysis · 2011
• Bufexamac and diclofenac: frequency of contact sensitization and absence of cross-reactions.Contact dermatitis · 1998

via PubMed